Botulinum Toxin A Versus Steroids for the Treatment of Chronic Plantar Fasciitis

Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Jul 18, 2014

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a treatment called Botulinum Toxin A (BTX-A) compared to steroid injections for people with chronic plantar fasciitis, which is a common cause of heel pain. The researchers believe that injecting BTX-A into specific calf muscles might help address the problem at its source, rather than just relieving the pain temporarily. Currently, there isn't enough evidence to say which treatment is better, so this study aims to fill that gap by comparing BTX-A to a saline (harmless saltwater) injection and the well-known steroid injection.

To participate in this trial, individuals must have been experiencing plantar fasciitis symptoms for more than three months and have not found relief from other treatments in the past three months. Key eligibility requirements include having clear signs of plantar fasciitis on an MRI and providing written consent to take part. Participants will receive either the BTX-A injection, a steroid injection, or a saline injection, and they will be monitored throughout the study to see how well each treatment works. This research is important because it may help improve treatment options for people suffering from this painful condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical symptoms of a plantar fasciitis
• • Plantar fasciitis in MRI
• • Exclusion of differential diagnoses
• • Symptoms more than 3 months
• • Absolution of 3 months unsuccessful treatment
• • Written informed consent
• • Exclusion Criteria
• • Active differential diagnoses
• • Contraindications: pregnancy and breastfeeding, infection at injection sites, allergy against BTX-A
• • Previous injections or surgery for plantar fasciitis
• • Neurological diseases affecting the peripheral nervous system